Skip to main content

Table 1 Characteristics of observed RA patient samples

From: Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis

Characteristics

Total patient population

Patients with anti-TNF as second bDMARD

Patients with non-anti-TNF as second bDMARD

P value (anti-TNF versus non-anti-TNF)

N

451

(100.00%)

340

(100.00%)

111

(100.00%)

 

Age [in years], mean (SD)

53.75

(12.77)

52.96

(SD: 13.25)

56.17

(SD: 10.85)

0.055

Female gender, n (%)

351

(77.83%)

263

77.35%

88

79.28%

0.671

Mean CCI

2.09

(SD: 1.68)

2.11

(SD: 1.70)

2.03

(SD: 1.59)

0.786

First anti-TNF agent, n (%)

• Adalimumab

• Certolizumab

• Etanercept

• Golimumab

• Infliximab

177

17

182

42

33

(39.25%)

(3.77%)

(40.35%)

(9.31%)

(7.32%)

136

10

136

30

28

(40.00%)

(2.94%)

(40.00%)

(8.82%)

(8.24%)

41

7

46

12

5

(36.94%)

(6.31%)

(41.44%)

(10.81%)

(4.50%)

0.566

0.106

0.788

0.532

0.190

Duration of first anti-TNF treatment [in days]

• Mean (SD)

• Median (range)

357.71

272.00

(SD: 265,16)

(1061.00)

348.92

263.50

(SD: 263,81)

(1039.00)

384.60

315.00

(SD: 268,67)

(1059.00)

0.167

At least one prescription of … within 6 months before index date, n (%)

• sDMARDs

216

(47.89%)

160

(47.06%)

56

(50.45%)

0.535

• Painkillers/NSARs

317

(70.29%)

234

(68.82%)

83

(74.77%)

0.234

• Corticosteroids

326

(72.28%)

230

(67.65%)

96

(86.49%)

<0.001

At least one prescription of … within 6 months after index date**, n (%)

• sDMARDs

202

(44.79%)

157

(46.18%)

45

(40.54%)

0.300

• Painkillers/NSARs

313

(69.40%)

234

(68.82%)

79

(71.17%)

0.641

• Corticosteroids

318

(70.51%)

225

(66.18%)

93

(83.78%)

<0.001

  1. Legend: This table depicts the characteristics of the patients who were observed during this study
  2. Notes: Age is calculated at start of first anti-TNF treatment, CCI was calculated based on in- and outpatient diagnosis within 6 months before first anti-TNF agent was prescribed; in case first anti-TNF prescription was documented in the first half of 2010, the first 6 months of 2010 were used for CCI calculation
  3. Abbreviations: SD standard deviation, CCI Charlson Comorbidity Index